Segment Information

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 13: Segment Information

We have two operating segments—human pharmaceutical products and animal health. Our operating segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.

	Three Months Ended March 31,
	2016		2015
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology:
Humalog®	$	606.3	$	684.0
Humulin®	356.4		315.7
Forteo®	318.6		293.0
Trulicity®	143.6		18.3
Trajenta	94.4		82.3
Evista®	33.4		66.8
Other Endocrinology	204.0		166.2
Total Endocrinology	1,756.7		1,626.3
Oncology:
Alimta	564.2		573.0
Erbitux	168.1		88.2
Cyramza®	131.0		67.5
Other Oncology	31.2		30.3
Total Oncology	894.5		759.0
Cardiovascular:
Cialis®	576.7		538.3
Effient	131.5		121.8
Other Cardiovascular	46.0		55.1
Total Cardiovascular	754.2		715.2
Neuroscience:
Zyprexa®	212.8		219.5
Cymbalta	198.7		287.0
Strattera®	188.1		173.7
Other Neuroscience	44.1		45.1
Total Neuroscience	643.7		725.3
Other pharmaceuticals	61.4		69.1
Total human pharmaceutical products	4,110.5		3,894.9
Animal health	754.6		749.8
Revenue	$	4,865.1	$	4,644.7

	Three Months Ended March 31,
	2016			2015
Segment profits:
Human pharmaceutical products	$	927.0		$	1,083.1
Animal health	147.6			115.0
Total segment profits	$	1,074.6		$	1,198.1
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	1,074.6		$	1,198.1
Other profits (losses):
Acquired in-process research and development (Note 3)	—			(256.0		)
Amortization of intangible assets	(172.5		)	(152.7		)
Asset impairment, restructuring, and other special charges (Note 5)	(131.4		)	(108.0		)
Venezuela charge (Note 12)	(203.9		)	—
Inventory fair value adjustment related to Novartis AH (Note 3)	—			(63.5		)
Consolidated income before taxes	$	566.8		$	617.9

For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.